Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, affecting an estimated 2.7-3.9 million persons. 1 Among patients with cancer, the estimated prevalence of HCV infection is up to 30%. 2, 3 In cancer patients with chronic HCV infection receiving chemotherapy, exacerbation and reactivation of HCV infection are recognized as causes of liver dysfunction. [4] [5] [6] Exacerbation of HCV infection is defined as a threefold or greater rise in alanine aminotransferase (ALT) level in a patient without other causes of liver dysfunction, such as malignant infiltration, certain drugs, systemic infections affecting the liver, receipt of blood transfusion within 1 month of ALT elevation or GVHD of the liver. 5 Reactivation of HCV infection is defined as a rise in the HCV RNA level of at least 1 log 10 IU/mL from baseline, as HCV RNA levels in chronically-infected patients may fluctuate by about 0.5 log 10 IU/mL. 4, 5 Cancer patients with chronic HCV infection who undergo hematopoietic cell transplant (HCT) are at high risk for accelerated progression of liver fibrosis-progression can be twice as fast as in HCV-infected patients not undergoing HCT-and death due to infectious causes and GVHD. 7, 8 Currently available information suggests that compared with hepatitis B virus reactivation, HCV reactivation rarely causes significant liver-related morbidity and mortality. 4, 5, 9, 10 However, little is known about the natural course or outcomes of HCV exacerbation and reactivation in HCT recipients. Recently published task force guidelines for treatment of chronic HCV infection in HCT candidates recommend completing antiviral treatment before HCT when possible. 11 However, in patients who cannot delay HCT because of the risk of cancer relapse, deferring antiviral therapy until 6 months after HCT is the most common approach. At this point, most patients will have finished immunosuppressive therapy, which can cause toxic effects overlapping with those of antivirals and drug-drug interactions with antivirals. 11 Immediate antiviral treatment after HCT is recommended only in patients who develop fibrosing cholestatic hepatitis or decompensated cirrhosis and in patients with HCV-related lymphoproliferative disorders. 11 Whether HCV reactivation during HCT warrants urgent antiviral treatment has not been established. 11 Herein, we describe what to our knowledge is the first reported case of HCV exacerbation and reactivation complicating the early HCT period (o 30 days after HCT) and necessitating urgent HCV-targeted therapy. A 25-year old man with chronic HCV infection (genotype 2) and stage II primary mediastinal B-cell lymphoma had relapsed disease 6 months after 6 cycles of rituximab, cyclophosphamide, doxorubicin, VCR and prednisolone. He then received rituximab, ifosfamide, carboplatin and etoposide, which produced CR after 3 cycles. He was then hospitalized for an autologous HCT with a conditioning regimen consisting of gemcitabine, busulfan, melphalan and vorinostat. He achieved engraftment by day 9. At baseline, before conditioning, the HCV viral load was 696 000 IU/mL (5.8 log 10 IU/mL) (HCV RNA quantitative PCR, version 2.0; Roche Molecular Systems, Inc., Pleasanton, CA, USA) (Figure 1) , and he was without evidence of cirrhosis based on abdominal imaging and noninvasive serumbased fibrosis testing with FIBROSpect II (Prometheus Laboratories, San Diego, CA). Although surveillance HCV viral load testing peritransplant is not routinely recommended, 11 such testing was performed 1 day after the start of conditioning therapy and showed an increase in the viral load of 42 logs to 7.9 log 10 IU/mL. This was accompanied by a rise in the ALT level within 1 week of initiation of the conditioning regimen and 2 days after HCT. The bilirubin level also peaked during this period to 8.3 mg/dL. The ALT and bilirubin levels normalized 9 days after HCT, but quickly increased again after hospital discharge and progressed to include fevers, chills, nausea and vomiting. The patient was re-hospitalized for investigation of the rising liver enzyme levels and symptoms. During this hospitalization, the HCV viral load increased to 4100 000 000 IU/mL (48 log 10 IU/mL). Other causes of acute hepatitis were excluded, including HSV, hepatitis A virus, hepatitis B virus, hepatitis E virus, CMV, adenovirus, bacterial and fungal infections and drugs. Liver sonography showed an enlarged liver, mild coarse echotexture and normal portal and hepatic veins. Liver biopsy was precluded by thrombocytopenia.
Because of the persistently elevated ALT levels, the decision was made to start HCV antiviral therapy 20 days after HCT. This decision was also based on concerns about impending hepatic failure and possible development of fibrosing cholestatic hepatitis, 12 along with a desire to reduce the patient's risk of future lymphoma relapse. 5 The patient received the direct-acting antiviral (DAA) combination of sofosbuvir (400 mg orally daily) and daclatasvir (60 mg orally daily) for a 12-week course. Despite the genotype 2 HCV infection, ribavirin was precluded because of anemia (peritransplant nadir hemoglobin of 7.9 g/dL). After 3 days of therapy, the ALT level precipitously decreased, the HCV viral load declined over 2 logs, and symptoms improved. A liver biopsy was ultimately performed 4 weeks into DAA therapy because of persistently elevated conjugated bilirubin levels, and it revealed chronic portal inflammation (grade 2), bile duct injury and moderate cholestasis. HCV antiviral therapy ended at 12 weeks, at which point the HCV viral load was undetectable, and the ALT elevation and hyperbilirubinemia was fully resolved. The viral load remains undetectable at week 4 without antivirals.
Treatment of HCV can positively impact cancer patients' virologic, hepatic and oncologic outcomes. 5, 13 In cancer patients with untreated HCV receiving chemotherapy, the incidence of acute HCV reactivation has been reported to be 11%, and reactivation is more common in patients with hematologic malignancies than in those with solid tumors. 4 During exacerbation, liver dysfunction can cause discontinuation of chemotherapy or interruption in the planned treatment course. 4, 10 Chronic HCV infection has been linked to the pathogenesis of B-cell nonHodgkin lymphoma, and HCV treatment is recommended as initial therapy in select patients with certain types of lymphoma, such as splenic marginal zone lymphoma.
14 In HCT recipients with chronic HCV infection, patients who received HCV treatment before or after HCT had a lower incidence of relapse of HCV-associated nonHodgkin lymphoma than patients who did not receive such therapy (20 vs 86%, P = 0.015). HCT recipients treated for HCV infection also had higher 5-year survival rates (75 vs 39%, P = 0.02) than those not treated for HCV infection. 5 Furthermore, HCV-infected cancer patients who are not treated for HCV have a greater risk of progression to cirrhosis and portal hypertension, which may make oncologic treatment challenging because of impaired chemotherapy drug metabolism and clearance. 13 All HCT candidates and recipients should be evaluated for HCV treatment; however, the appropriate timing of HCV treatment has not been established. 11 DAAs are safe and well-tolerated in HCT candidates, and they may be more effective for treatment of HCV than interferon-containing regimens.
5 Drug-drug interactions and HCV treatment outcomes in patients receiving chemotherapy with novel DAAs are not well established and need to be further investigated.
In our experience, most patients with HCV exacerbation or reactivation experience normalization of liver function tests with return to baseline levels of viremia when chemotherapy is discontinued. [4] [5] [6] In the patient describe herein, the severe and sustained HCV reactivation prompted early (o 30 days after HCT) antiviral treatment to prevent further hepatic damage and improve overall outcome. Severe HCV exacerbation or reactivation in the early post-HCT period should be added to the indications for urgent HCV treatment.
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